HK1054697A1 - Pharmaceutical preparations - Google Patents
Pharmaceutical preparationsInfo
- Publication number
- HK1054697A1 HK1054697A1 HK03107084A HK03107084A HK1054697A1 HK 1054697 A1 HK1054697 A1 HK 1054697A1 HK 03107084 A HK03107084 A HK 03107084A HK 03107084 A HK03107084 A HK 03107084A HK 1054697 A1 HK1054697 A1 HK 1054697A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- formulations
- release
- relates
- fusion
- pharmaceutical formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Abstract
The invention relates to novel oral pharmaceutical formulations having a variably adjustable release effect . Said formulations contain one or several sucrose fatty acid esters as exclusive release control agents, in addition to one or several active ingredients. The invention also relates to a method for the production of the formulations by fusion granulation or fusion pelletizing . The novel pharmaceutical formulations range from quick release to delayed release medicament forms.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2000110509 DE10010509A1 (en) | 2000-03-08 | 2000-03-08 | Oral pharmaceutical formulations with controllable release characteristics, e.g. rapid or delayed release, contain sucrose fatty acid ester as drug release controlling agent |
US18796200P | 2000-03-09 | 2000-03-09 | |
PCT/EP2001/002500 WO2001066081A2 (en) | 2000-03-08 | 2001-03-06 | Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1054697A1 true HK1054697A1 (en) | 2003-12-12 |
Family
ID=26004678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03107084A HK1054697A1 (en) | 2000-03-08 | 2003-09-30 | Pharmaceutical preparations |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1267828B1 (en) |
JP (1) | JP2003528829A (en) |
KR (1) | KR20020083171A (en) |
CN (1) | CN1212831C (en) |
AT (1) | ATE334659T1 (en) |
AU (1) | AU2001250365A1 (en) |
BG (1) | BG107064A (en) |
BR (1) | BR0109036A (en) |
CA (1) | CA2339913C (en) |
CZ (1) | CZ20023009A3 (en) |
DE (1) | DE50110617D1 (en) |
EA (1) | EA200200951A1 (en) |
EE (1) | EE200200504A (en) |
GE (1) | GEP20053455B (en) |
HK (1) | HK1054697A1 (en) |
HR (1) | HRP20020804B1 (en) |
HU (1) | HUP0204513A3 (en) |
IS (1) | IS6511A (en) |
NO (1) | NO20024237L (en) |
NZ (1) | NZ521215A (en) |
PL (1) | PL202935B1 (en) |
SK (1) | SK13252002A3 (en) |
WO (1) | WO2001066081A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1490031A1 (en) * | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
CA2509259A1 (en) * | 2003-01-23 | 2004-08-05 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
DE10341264A1 (en) * | 2003-09-04 | 2005-03-24 | Grünenthal GmbH | Melt-formulated, multiparticulate oral dosage form |
JP2007533733A (en) * | 2004-04-22 | 2007-11-22 | モル リサーチ アプリケーションズ リミテッド | How to control food intake |
AU2009270768A1 (en) * | 2008-07-18 | 2010-01-21 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
DE102009013613A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Dry processing of retigabine |
DE102009013612A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabine tablets, preferably with modified release |
DE102009013611A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Solid retigabine in non-crystalline form |
BR112012018173A2 (en) * | 2010-01-20 | 2017-08-29 | Valeant Pharmaceuticals Int | "MODIFIED RELEASE FORMULATION AND METHOD OF USE" |
EP2729176A1 (en) | 2011-07-05 | 2014-05-14 | Contera Pharma APS | The use of serotonin receptor agonists for treatment of movement disorders |
US9616025B2 (en) * | 2013-10-29 | 2017-04-11 | Echo Pharmaceuticals B.V. | Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment |
US11331268B2 (en) * | 2016-11-18 | 2022-05-17 | The University Of Western Australia | Taste masking product |
CN107441055A (en) * | 2017-08-03 | 2017-12-08 | 山东则正医药技术有限公司 | A kind of preparation method of controlled release drug |
CN108853044B (en) * | 2018-07-06 | 2020-11-06 | 郑州明泽医药科技有限公司 | Nifedipine sustained release tablet and preparation method thereof |
CN109679147B (en) * | 2018-12-28 | 2021-05-11 | 广西科技师范学院 | Plant microfine fiber sucrose fatty acid ester enrichment and preparation method thereof |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
WO2021145625A1 (en) * | 2020-01-13 | 2021-07-22 | 한국유나이티드제약 주식회사 | Pharmaceutical composition comprising r-thioctic acid or pharmaceutically acceptable salt thereof and enteric coating base material |
CN111513192A (en) * | 2020-05-19 | 2020-08-11 | 北京中联华康科技有限公司 | Esterified cysteamine hydrochloride stable powder and preparation method and application thereof |
CN114983964B (en) * | 2022-06-24 | 2024-05-03 | 广东恒健制药有限公司 | Cefdinir granule and preparation method thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63101320A (en) * | 1986-10-17 | 1988-05-06 | Dainippon Pharmaceut Co Ltd | Calcium valproate preparation |
JPH07267850A (en) * | 1994-03-28 | 1995-10-17 | Eisai Co Ltd | Medicine composition prevented in unpleasant taste and method for producing the same |
JP4078567B2 (en) * | 1997-04-25 | 2008-04-23 | 東和薬品株式会社 | Sustained release microcapsules and production method thereof |
JP4299384B2 (en) * | 1997-07-15 | 2009-07-22 | 富山化学工業株式会社 | Anti-elution delay fine granules |
HU230889B1 (en) * | 1998-03-26 | 2018-12-28 | Astellas Pharma Inc. | Sustained release preparations |
DE19840152A1 (en) * | 1998-09-03 | 2000-03-09 | Dresden Arzneimittel | Pharmaceutical compositions containing calcium valproate with a delayed release of active substance, process for their preparation and their use |
DE19916383A1 (en) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmaceutical composition with an extrusion |
-
2001
- 2001-03-06 CN CNB018061893A patent/CN1212831C/en not_active Expired - Fee Related
- 2001-03-06 NZ NZ521215A patent/NZ521215A/en unknown
- 2001-03-06 DE DE50110617T patent/DE50110617D1/en not_active Revoked
- 2001-03-06 PL PL362547A patent/PL202935B1/en not_active IP Right Cessation
- 2001-03-06 JP JP2001564734A patent/JP2003528829A/en active Pending
- 2001-03-06 EA EA200200951A patent/EA200200951A1/en unknown
- 2001-03-06 BR BR0109036-4A patent/BR0109036A/en not_active Application Discontinuation
- 2001-03-06 HU HU0204513A patent/HUP0204513A3/en unknown
- 2001-03-06 CZ CZ20023009A patent/CZ20023009A3/en unknown
- 2001-03-06 EE EEP200200504A patent/EE200200504A/en unknown
- 2001-03-06 AT AT01923641T patent/ATE334659T1/en not_active IP Right Cessation
- 2001-03-06 SK SK1325-2002A patent/SK13252002A3/en not_active Application Discontinuation
- 2001-03-06 WO PCT/EP2001/002500 patent/WO2001066081A2/en active IP Right Grant
- 2001-03-06 AU AU2001250365A patent/AU2001250365A1/en not_active Abandoned
- 2001-03-06 KR KR1020027011672A patent/KR20020083171A/en not_active Application Discontinuation
- 2001-03-06 EP EP01923641A patent/EP1267828B1/en not_active Revoked
- 2001-03-06 GE GE4946A patent/GEP20053455B/en unknown
- 2001-03-07 CA CA002339913A patent/CA2339913C/en not_active Expired - Fee Related
-
2002
- 2002-08-20 IS IS6511A patent/IS6511A/en unknown
- 2002-09-05 BG BG107064A patent/BG107064A/en unknown
- 2002-09-05 NO NO20024237A patent/NO20024237L/en not_active Application Discontinuation
- 2002-10-07 HR HR20020804A patent/HRP20020804B1/en not_active IP Right Cessation
-
2003
- 2003-09-30 HK HK03107084A patent/HK1054697A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2001066081A2 (en) | 2001-09-13 |
WO2001066081A3 (en) | 2002-03-14 |
NO20024237D0 (en) | 2002-09-05 |
PL362547A1 (en) | 2004-11-02 |
AU2001250365A1 (en) | 2001-09-17 |
HRP20020804B1 (en) | 2008-06-30 |
HRP20020804A2 (en) | 2004-12-31 |
HUP0204513A2 (en) | 2003-05-28 |
EP1267828B1 (en) | 2006-08-02 |
NZ521215A (en) | 2005-04-29 |
SK13252002A3 (en) | 2003-07-01 |
EE200200504A (en) | 2004-02-16 |
NO20024237L (en) | 2002-09-05 |
PL202935B1 (en) | 2009-08-31 |
EP1267828A2 (en) | 2003-01-02 |
EA200200951A1 (en) | 2003-02-27 |
GEP20053455B (en) | 2005-02-25 |
CZ20023009A3 (en) | 2003-06-18 |
CN1418091A (en) | 2003-05-14 |
CN1212831C (en) | 2005-08-03 |
IS6511A (en) | 2002-08-20 |
KR20020083171A (en) | 2002-11-01 |
BR0109036A (en) | 2003-03-18 |
ATE334659T1 (en) | 2006-08-15 |
BG107064A (en) | 2003-04-30 |
JP2003528829A (en) | 2003-09-30 |
HUP0204513A3 (en) | 2004-06-28 |
CA2339913C (en) | 2009-02-24 |
CA2339913A1 (en) | 2001-09-08 |
DE50110617D1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1054697A1 (en) | Pharmaceutical preparations | |
IL158589A (en) | Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators | |
TNSN01108A1 (en) | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | |
WO2001098290A3 (en) | Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
IL145430A0 (en) | N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same | |
WO2001087329A8 (en) | Liquid pharmaceutical composition containing an erythropoietin derivate | |
WO2001095856A3 (en) | Urea derivative useful as an anti-cancer agent and process for preparing same | |
WO2004078105A3 (en) | Fondaparinux sodium composition of high purity, method for production of said composition and pharmaceutical compositions containing the same as active ingredient | |
FR2743075B1 (en) | PROCESS FOR THE PREPARATION OF ACTIVE SUBSTANCES FROM NACRE, PRODUCTS OBTAINED, USEFUL IN PARTICULAR AS MEDICAMENTS | |
MXPA02012889A (en) | 4-alkoxy cyclohexane-1 amino carboxylic acid esters and method for the production thereof. | |
NO20023551D0 (en) | Ibuprofen-containing active agent preparation | |
WO2007078848A3 (en) | Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid | |
BR0311642A (en) | Increased Release Sodium Divalproex Formulation | |
HUP0600084A2 (en) | Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient | |
AU2421601A (en) | Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation | |
MXPA03010596A (en) | Granular preparations of gaboxadol. | |
YU66902A (en) | Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients | |
CA2429793A1 (en) | Interferon therapeutic effect enhancer | |
AU2003224107A1 (en) | Soluble composition containing sporopollenin and the use thereof | |
WO2002030391A3 (en) | Method for determining the release of a peptide from a sustained release polylactide formulation | |
AU2001274138A1 (en) | Propanolaminotetralines, preparation thereof and compositions containing same | |
BG106236A (en) | Melt granulation | |
PL1668003T3 (en) | Benzisoxazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: CORRECTION OF THE PRIORITY COUNTRY CODE FROM DE TO US |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20100306 |